113. 筋ジストロフィー Muscular dystrophy Clinical trials / Disease details
臨床試験数 : 622 / 薬物数 : 485 - (DrugBank : 99) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 168
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05154851 (ClinicalTrials.gov) | October 1, 2020 | 9/12/2021 | Individual Patient Expanded Access IND for the Treatment of Spinal Cord Injury, and Congenital Muscular Dystrophy. | Individual Patient Expanded Access IND for the Treatment of Spinal Cord Injury, and Congenital Muscular Dystrophy. | Spinal Cord Injuries;Congenital Muscular Dystrophy Due to Lamin A/C Mutation | Biological: HB-adMSCs | Hope Biosciences Stem Cell Research Foundation | NULL | No longer available | N/A | N/A | Male | United States | ||
| 2 | NCT03067831 (ClinicalTrials.gov) | September 2015 | 25/2/2017 | Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy | Safety and Efficacy of Purified Autologous Bone Marrow-Derived Stem Cell Therapy for Patients With Duchenne Muscular Dystrophy. | Duchenne Muscular Dystrophy | Biological: Stem Cells | Stem Cells Arabia | NULL | Recruiting | 4 Years | 25 Years | All | 20 | Phase 1/Phase 2 | Jordan |
| 3 | NCT02484560 (ClinicalTrials.gov) | June 2015 | 16/6/2015 | Efficacy of Stem Cell Therapy in Ambulatory and Non-ambulatory Children With Duchenne Muscular Dystrophy - Phase 1-2 | Efficacy of Allogenic Mesenchymal Stem Cell Therapy in Ambulatory and Non-ambulatory Children With Duchenne Muscular Dystrophy - Phase 1-2 | Duchenne Muscular Dystrophy | Drug: Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell | University of Gaziantep | Istinye University, Cukurova University, Yildirim Beyazit University, Gaziantep Deva Hospital, Gaziantep Public Hospital | Active, not recruiting | 8 Years | 14 Years | Male | 10 | Phase 1 | Turkey |
| 4 | NCT01834066 (ClinicalTrials.gov) | September 2014 | 26/2/2013 | Study Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Muscular Dystrophy. | Safety and Efficacy of Bone Marrow Autologous Cells in Muscular Dystrophy. It is Self Funded (Patients' Own Funding) Clinical Trial | Muscular Dystrophy;Duchenne Muscular Dystrophy, | Biological: Stem Cell | Chaitanya Hospital, Pune | NULL | Recruiting | 6 Years | 25 Years | Both | 25 | Phase 1/Phase 2 | India |
| 5 | NCT02235844 (ClinicalTrials.gov) | September 2014 | 8/9/2014 | Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (DMD) | Allogeneic Transplantation of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) for a Single Male Patient With Duchenne Muscular Dystrophy (DMD) | Duchenne's Muscular Dystrophy | Biological: Umbilical Cord Mesenchymal Stem Cells | Allergy and Asthma Consultants, Wichita, Kansas | Aidan Foundation;Neil H. Riordan PhD | Completed | 28 Years | 31 Years | Male | 1 | Phase 1 | United States |
| 6 | NCT02285673 (ClinicalTrials.gov) | November 2013 | 5/11/2014 | Efficacy of Umbilical Cord Mesenchymal Stem Cells in Duchenne Muscular Dystrophy | Efficacy of Umbilical Cord Mesenchymal Stem Cells in Duchenne Muscular Dystrophy: Phase 1/2 Study | Duchenne Muscular Dystrophy | Biological: Umbilical Cord Mesenchymal Stem Cell | Acibadem University | NULL | Recruiting | 7 Years | 20 Years | Male | 10 | Phase 1/Phase 2 | Turkey |
| 7 | NCT01610440 (ClinicalTrials.gov) | October 2011 | 21/5/2012 | Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Duchenne Muscular Dystrophy | Phase I/II Study of Stem Cell Therapy in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Biological: human umbilical cord mesenchymal stem cells | Shenzhen Beike Bio-Technology Co., Ltd. | The Second Affiliated Hospital of Kunming Medical University | Recruiting | 5 Years | 12 Years | Both | 15 | Phase 1/Phase 2 | China |
| 8 | NCT02245711 (ClinicalTrials.gov) | December 2010 | 12/9/2014 | Cell Therapy in Limb Girdle Muscular Dystrophy | Intrathecal Autologous Mononuclear Cell Therapy for Limb Girdle Muscular Dystrophy | Limb Girdle Muscular Dystrophy | Biological: Stem Cell | Neurogen Brain and Spine Institute | NULL | Withdrawn | 15 Years | 60 Years | All | 0 | Phase 1 | India |
| 9 | NCT02241928 (ClinicalTrials.gov) | January 2009 | 12/9/2014 | Stem Cell Therapy in Muscular Dystrophy | Role of Autologous Mononuclear Cell Therapy in Muscular Dystrophy | Muscular Dystrophy | Biological: Stem Cell | Neurogen Brain and Spine Institute | NULL | Withdrawn | 6 Months | 60 Years | All | 0 | Phase 1 | India |
| 10 | NCT02241434 (ClinicalTrials.gov) | January 2009 | 12/9/2014 | Stem Cell Therapy in Duchenne Muscular Dystrophy | The Role of Autologous Bone Marrow Mononuclear Cell Therapy in Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Biological: Stem Cell | Neurogen Brain and Spine Institute | NULL | Withdrawn | 3 Years | 25 Years | All | 0 | Phase 1 | India |
| 11 | NCT02050776 (ClinicalTrials.gov) | December 2008 | 29/1/2014 | Stem Cell Therapy in Limb Girdle Muscular Dystrophy | The Role of Cell Therapy in Modifying the Course of Limb Girdle Muscular Dystrophy- A Longitudinal 5-year Study | Limb Girdle Muscular Dystrophy | Biological: Autologous bone marrow mononuclear cell transplantation | Neurogen Brain and Spine Institute | NULL | Withdrawn | 15 Years | 60 Years | All | 0 | Phase 1 | India |